Menopausing — Davina McCall & Dr Naomi Potter¶
This note is an AI-generated, full-text extraction intended to make the book's arguments legible without pretending to replace the source. It separates the author's claims, evidence, practical advice, and limitations; verify anything load-bearing against the book or a primary source.
Executive summary¶
Menopausing is a popularised, advocacy-driven guide to perimenopause and menopause that blends Davina McCall's personal narrative with Dr Naomi Potter's medical explanations. The book argues that women suffer unnecessarily due to widespread ignorance, medical dismissal, and outdated fears about hormone replacement therapy (HRT). It positions modern transdermal HRT as largely safe and effective, calling for a cultural "uprising" to destigmatise menopause and improve medical training. The book is primarily anecdotal and prescriptive rather than rigorously empirical, with heavy reliance on McCall's own experience and reader-submitted testimonies. While it succeeds in validating women's experiences and providing accessible information, it overstates HRT benefits, underplays risks and contraindications, and presents a one-sided view of menopause management.
The central thesis¶
Women suffer unnecessarily during perimenopause and menopause due to three interconnected problems: generational silence and shame about menopause, inadequate medical training leading to dismissal and misdiagnosis, and persistent myths about HRT stemming from the 2002 Women's Health Initiative study. The authors argue that modern transdermal HRT is largely safe and effective, that no woman should "lose years of her life" to untreated symptoms, and that collective action—open conversation, self-advocacy, and political pressure—can transform the menopausal experience. The title Menopausing implies deliberate, conscious engagement with the transition rather than passive suffering.
Argument map¶
Part One: The Problem establishes that perimenopause is a hidden crisis. McCall argues that women suffer in silence because menopause was never discussed in their families or communities, and that doctors routinely dismiss symptoms or misprescribe antidepressants. The 2002 WHI study is identified as the root cause of enduring HRT fear. Evidence is almost entirely anecdotal—McCall's personal story and reader testimonies.
Part Two: The Solution presents education and HRT as the primary answers. Dr Potter explains hormones, perimenopause vs. menopause, and why blood tests are unreliable for diagnosis. Modern transdermal HRT is presented as safe and beneficial, with claims about osteoporosis, cardiovascular disease, and dementia prevention. Testosterone is introduced as an additional treatment.
Part Three: Practical Advice covers relationships, sexual health, exercise, nutrition, skincare, and activism. The tone shifts from clinical to motivational, with advice ranging from evidence-informed (exercise for bone health) to entirely anecdotal (wearing matching underwear to boost confidence).
Core concepts and frameworks¶
Perimenopause vs. menopause: Menopause is strictly 12 consecutive months without a period (average age 51). Perimenopause is the transition phase lasting 4–8 years, during which hormones fluctuate wildly. Crucially, period changes are often one of the last symptoms, not the first.
Perimenopause as "master of disguise": Symptoms can manifest in nearly every body system—brain fog, joint pain, heart palpitations, tinnitus, electric shock sensations, histamine intolerance—making diagnosis challenging.
Clinical diagnosis over blood tests: Perimenopausal hormone levels fluctuate too much for single blood tests to be reliable. NICE guidelines are cited as authority: for women over 45 with typical symptoms, HRT should be first-line treatment without blood tests.
Modern transdermal HRT: Patches, gels, and sprays that bypass the liver are presented as superior to oral tablets, with no increased risk of blood clots, stroke, or gallbladder disease. Body-identical hormones (17-beta estradiol) are distinguished from older horse urine-derived formulations.
The WHI study as foundational error: The 2002 Women's Health Initiative study is criticised for using older women (average age 63), a single dose and type of HRT, and synthetic progestogen. The authors claim re-analysis shows no increased risk of death from heart disease or breast cancer for women aged 50–59.
Detailed chapter or part walk-through¶
Introduction¶
McCall recounts her perimenopausal journey beginning at age 44 (2012) during a photo shoot in Prague. She describes night sweats so severe she would wake up with "a pool of water" in her neck, skin changes including dryness and "crepe-y" texture, vaginal dryness causing pain during urination, cognitive symptoms including forgetting names during live TV and putting objects in bizarre places (phone in fridge, keys in bin), mood changes including anger and irritability, joint pain, and vision changes affecting her ability to read autocue. She explicitly compares the sweating to her past heroin withdrawal.
McCall describes her three-year journey from secrecy to advocacy, admitting she lied to friends about being on HRT, feeling ashamed and like she had "failed as a woman." She identifies a turning point where she sought private medical help after her GP dismissed her concerns, telling her she was "probably too young." She calls this "medical gaslighting."
Three "humungous problem areas" are identified: the attitude problem (generational secrecy rooted in Victorian-era life expectancy), lack of decent menopause training for GPs and gynaecologists, and HRT myths from the 2002 WHI study. McCall offers a three-step guide: get informed, speak up, be an ally. She proposes that women should be offered a menopause discussion appointment at age 45.
Chapter 1: "F*** Off. Where Are My Keys?"¶
This chapter consists almost entirely of reader-submitted testimonies with McCall's commentary. Key stories include: Sharon, prescribed antidepressants for three years before HRT was offered; Saz, told by her GP she was "burnt out" and should "sit down more"; Diane, offered antidepressants immediately despite not being depressed; Buck, a trans man whose testosterone caused severe atrophy leading to septic shock and near-death, where simple oestrogen cream could have prevented the crisis; Marie, diagnosed with Premature Ovarian Insufficiency at 27 while in the army, receiving a cold diagnosis with no fertility discussion, later discovering she had been on one-third of the correct oestrogen dose for 15 years; Jayne, who has muscular dystrophy and whose doctors used her pre-existing condition as a "scapegoat" to explain all menopause symptoms.
McCall's responses are emotionally supportive but not clinically detailed. She does not question or contextualise any testimonial, accepting all claims at face value. The chapter functions as validation and community-building rather than evidence-based analysis.
Chapter 2: Knowledge is Power: Perimenopause and Menopause Explained¶
Dr Potter provides the medical framework. Oestrogen, progesterone, and testosterone are explained as key hormones. Oestrogen has receptors throughout the body—affecting mood, memory, bone strength, and heart health. Progesterone regulates the menstrual cycle. Testosterone affects mood, sex drive, strength, and stamina.
The authors challenge blood tests as the gold standard for diagnosis, explaining that perimenopausal hormone levels fluctuate wildly. NICE guidelines are cited: for women over 45 with typical symptoms, HRT should be first-line treatment without blood tests. Expensive alternative tests (saliva, dried urine, hair sampling, DNA sampling) are dismissed as not recommended by the British Menopause Society.
Long-term health implications are presented: osteoporosis (oestrogen maintains bone density; HRT can improve it), cardiovascular disease (declining oestrogen increases CVD risk; heart disease kills more than twice as many UK women as breast cancer), and dementia (women with dementia outnumber men 2:1 globally; the authors argue it's "logical to assume" HRT prevents vascular dementia).
Chapter 3: From Dry Vag to Zits: Signs You Might Be Perimenopausal or Menopausal¶
This chapter catalogues an unexpectedly wide range of symptoms. Hot flushes and night sweats are claimed to affect eight out of ten women (uncited). Brain fog is described as a "horror" involving forgetfulness and word-finding difficulty. McCall recounts struggling six hours to recall the word "lawn." Heart palpitations required her to wear a heart monitor for a week; doctors confirmed the cause was hormonal after thorough testing.
Lesser-known symptoms include electric shock sensations ("elastic bands twanging under your skin"), dry mouth or "burning mouth," dry eyes, skin changes (one uncited study claims skin loses about one-third of collagen in first five years of menopause), hair changes (brittle, breaking hair, receding hairline), tinnitus, and histamine intolerance.
Dr Nighat Arif contributes a cultural perspective, arguing that menopause discourse is dominated by white, middle-class, Western perspectives. She identifies barriers for South Asian communities: no direct translation for "menopause" in Punjabi/Urdu—the closest term banjee means "barren"—and psychological symptoms don't translate well while physical symptoms are more commonly reported.
The chapter shifts abruptly to confidence-building advice: wearing matching underwear, walking with head up and shoulders back, listening to new music and podcasts, and never saying "I'm too old to know about that." This advice is entirely anecdotal.
Chapter 4: Early Menopause and Premature Ovarian Insufficiency¶
The authors argue that early menopause and Premature Ovarian Insufficiency (POI) are under-recognised, under-diagnosed, and under-treated. The older term "premature ovarian failure" (POF) is noted as psychologically damaging. Statistical claims include 1 in 100 women experiencing POI before age 40 and 5–10% chance of natural pregnancy following POI diagnosis, though no citations are provided.
Personal testimonies dominate: Natasha entered menopause at age 13, never had a period, was ashamed to tell anyone until age 25, developed osteoporosis, and only received testosterone at age 45. Aoife was diagnosed at 21 with POI likely from autoimmune disease, experienced hot flushes in secondary school, and miraculously conceived naturally at 26. Sima experienced menopause at 34 from pelvic radiotherapy for Stage 3 bowel cancer and found menopause "harder to come to terms with, and to get treatment for, than cancer."
Medical guidance includes diagnostic protocols for different age groups and the recommendation that HRT is first-line treatment, with NICE guidance recommending HRT at least until age 51 for POI/early menopause.
Chapter 5: Now For the Science Bit: HRT Demystified¶
McCall claims only 10% of women who could benefit from HRT actually take it (uncited). She positions HRT as comparable to insulin for diabetes or thyroxine for thyroid deficiency—merely replacing hormones the body is losing.
A clear hierarchy of delivery methods is established: transdermal oestrogen (patches, gel, spray) is presented as superior to oral tablets because it bypasses the liver, eliminating increased risk of blood clots, stroke, and gallbladder disease. Patches (e.g., Estradot 25–100 micrograms) are discreet but can peel off. Gel (Oestrogel pump or Sandrena sachets) allows tiny starting doses but requires drying time. Spray (Lenzetto) is quick-drying but harder to get on NHS.
Testosterone is presented as a "female hormone" produced in ovaries, with decline causing loss of libido, strength, and cognitive sharpness. McCall reports it was a "game-changer" for her personally. The core problem identified is that NHS-licensed testosterone products are only for men; GPs can prescribe "off-licence" but many are reluctant. McCall calls this "outrageous" and makes it her "next big focus."
Empirical claims include: transdermal oestrogen has "no increased risk of blood clots, stroke or gallbladder disease"; HRT can increase bone density by ~5% in two years and reduce spinal/hip fracture risk by 40%; HRT may reduce heart disease risk if started before age 60 or within 10 years of menopause; a 2021 study of 600,000+ women over 30 years found HRT not linked to increased dementia risk; a 2022 US study reported women on HRT for 6+ years were 79% less likely to develop Alzheimer's. None of these claims are cited within the excerpt.
Chapter 6: HRT: Debunking the Myths¶
The WHI study is identified as the root cause of "all-pervading mistrust of HRT." The authors argue the study's findings were devastatingly misreported and misunderstood due to: using only one dose and type of oestrogen (older, oral) and one type of progestogen (older, synthetic); wrong age group (mean age 63, some up to 79); premature halting; confounding factors (most participants were overweight); and high dropout rate.
A comparative risk table is presented: baseline 23 out of 1,000 women aged 50–59 will develop breast cancer over 5 years; combined HRT with synthetic progesterone increases to 27 out of 1,000; two or more units of alcohol daily increases to 28 out of 1,000; overweight or obese increases to 47 out of 1,000. The authors claim oestrogen-only HRT and oestrogen plus body-identical (micronised) progesterone are "not associated" with increased breast cancer risk.
Systemic barriers to accessing HRT are identified: lack of training (a 2021 survey of 33 UK medical schools found 41% did not have mandatory menopause education), lack of time in GP appointments, and the lingering shadow of the WHI study.
Chapter 7: Doctor, Doctor … I'm Not Depressed, I'm Menopausal¶
The authors argue that many women are being misdiagnosed with clinical depression and prescribed antidepressants when their mood symptoms are hormonally driven. A 2021 survey of 5,000 women found that one in four perimenopausal or menopausal women were prescribed antidepressants. The authors draw a historical parallel to the 1960s-1980s "Valium epidemic."
Suicide statistics are cited: women aged 45-54 have the highest suicide rate of any female age group (7 per 100,000), more than double the rate for 15-19 year olds. The authors present this as evidence that misdiagnosis has life-threatening consequences, though they do not establish causation.
Five women's stories follow a consistent pattern: presenting with mood symptoms, being dismissed or prescribed antidepressants, then improving after obtaining HRT. Margaret (age 42) had anxiety as her worst symptom, her marriage broke down, and she lost her will to live before improving "vastly" after starting HRT. Sally-Anne has a history of postpartum psychosis and is currently in a psychiatric hospital, struggling to convince psychiatrists of the link between hormonal flux and mental health crises.
Practical advice includes: explicitly mention "perimenopause" or "menopause" to the doctor; state symptoms and belief they are hormone-related; specify wanting to try HRT, not antidepressants. Coping strategies recommended include HRT, CBT, mindfulness, and exercise.
Chapter 8: The Dry Vagina Monologues¶
The authors argue that vaginal dryness (vulvovaginal atrophy) is extremely common but under-discussed. Statistical claims include "seven out of ten post-menopausal women suffer from vaginal dryness" and later "over half of post-menopausal women suffer from vaginal dryness"—an inconsistency with no source cited.
A crucial distinction is drawn between systemic HRT and topical vaginal oestrogen (creams, gels, pessaries, rings), which the authors claim is extremely safe, does not increase breast cancer or clot risk, and can be used indefinitely. Patient information leaflets are criticised as "misleading" because they list risks applicable to systemic HRT, not topical oestrogen.
Patient stories include: Alison (age 60) who had a decade of vaginal dryness misdiagnosed as cystitis, leading to suicidal thoughts; Sharon who suffered 12+ UTIs and 3 kidney infections over two years, with a male GP giving only basic hygiene advice before a female GP linked her symptoms to vaginal atrophy and prescribed vaginal pessaries; Claire whose dormant lichen sclerosus became severe during menopause, causing "indescribable" itching, fissures, blisters, and suicidal thoughts.
Treatment hierarchy includes systemic HRT, topical oestrogen options (creams, pessaries, rings), Senshio (ospemifene) as an oral tablet for women who cannot use local vaginal oestrogen, and non-hormonal options (vaginal moisturisers and lubricants with specific pH recommendations).
Chapter 9: Feeling Frisky: Why Great Sex Doesn't Stop at the Menopause¶
The chapter opens with two statistics from an unnamed survey: 84% of perimenopausal/menopausal women think an active sex life is important, and 80% say menopause has affected their sex drive. No source or methodology is cited.
A clear treatment sequence is presented: HRT first for fatigue, hot flushes, and low mood; topical oestrogen for vaginal dryness and recurrent UTIs; testosterone only after HRT is established. Samantha Evans, a former nurse and sex toy retailer described as a "sexpert," provides practical guidance on lubricant selection, warning against glycerin, propylene glycol, parabens, alcohol, dyes, perfumes, "tingling" ingredients, and glitter. She explicitly criticises KY Jelly for containing parabens and glycerin despite being "often recommended by doctors."
Evans lists seven benefits of masturbation and recommends specific vibrators, including the LELO Sona 2 described as a "game-changer." The authors argue that a cultural "sexual revolution" is underway, citing Lily Allen co-designing a vibrator as evidence.
Chapter 10: Batten Down the Hatches: How to Menopause-proof Your Relationships¶
Menopause is described as "akin to driving a 10-tonne steamroller through every meaningful relationship." The authors argue that partners also suffer—feeling "useless, powerless and rejected"—and deserve sympathy.
Rachael's story (age 40) illustrates cascading damage: multiple failed HRT attempts, daughter moving out due to mood swings, two redundancies, failed probation due to brain fog. Peter's story describes his wife chasing him with a baseball bat, initially blamed on malaria tablets. Alison's story describes a police officer who resigned due to brain fog and memory loss, later diagnosed as perimenopausal after starting HRT—no one asked why she was declining.
Practical advice includes: don't talk during symptoms; wait until feeling "relatively normal"; explain menopause to children as young as eight or nine; disclose symptoms to colleagues and bosses; if medical help and workplace accommodations don't resolve dissatisfaction, consider that the job itself may be wrong. The authors frame menopause as "a time of clarity" and introduce the concept of "re-branding ourselves."
Chapter 11: Dealing with Menopause Alongside Breast Cancer¶
This chapter argues that women with pre-existing or co-occurring conditions require highly individualised, specialist-led care. Heather's story describes a woman with a rare cancer who cannot take HRT and is proactively managing her health through lifestyle and monitoring. Kris's story describes extreme suffering from PMDD (suicidal thoughts) and relief from hysterectomy, but fear that HRT will trigger a return of PMDD symptoms, leading her to refuse all treatment despite feeling her "body is calling out for what it's missing." Sophie's story describes surgical menopause and thyroid disease, where a specialist switched her from gel to patches and prescribed testosterone, leading to significant improvement.
Dr Potter provides statistics: endometriosis affects 1 in 10 women of reproductive age in the UK; prevalence in women with infertility can be as high as 30-50%; women are 10 times more likely to suffer from thyroid disorders than men; a 2021 UK study of 836 women living with HIV found a third reported severe menopausal symptoms but less than half had heard of HRT and less than one in ten used it.
Chapter 12: Other Conditions and Menopause¶
This chapter continues the theme of complex interactions between menopause and other health conditions. The authors emphasise that women with conditions like PMDD and endometriosis are particularly sensitive to hormonal fluctuations, making starting HRT a potential trigger for symptoms. The interplay between menopause and other conditions is acknowledged as poorly understood due to lack of research.
Chapter 13: I See You – and You Look F* Great: Positive Changes During the Change¶
This chapter argues that exercise, nutrition, and self-care are "non-negotiables" for managing menopause. McCall recounts her fitness history and reports that HRT restored her energy and focus, enabling her to resume exercise. Practical recommendations include 30 minutes, 5 days/week (minimum 3), using weekly planners, scheduling exercise like appointments, and mood-matching activities (boxing for anger, Pilates for sadness).
McCall acknowledges she is "not a dietitian" and her nutrition approach is based on personal experience. She claims metabolism slows with age and weight loss requires a "two-pronged attack" of 20% exercise and 80% food (no source cited). She states HRT does not directly cause weight loss but may provide motivation by alleviating symptoms.
Guest contributors provide specialised advice. Caroline Hirons explains that falling oestrogen reduces the skin's ability to retain ceramides, and warns against the "moneypause" industry exploiting women. Cheryl Phelps-Gardiner provides a five-minute makeup routine with specific brand recommendations (Chanel, YSL, Laura Mercier, NARS). Michael Douglas identifies four causes of hair problems: natural ageing, hormones, genes, and diet, recommending HRT, adequate protein (55-60g daily), collagen supplements, and minoxidil for female pattern hair loss.
McCall advises readers to consciously stop groaning when bending down, walk with purpose, and reframe menopause as a "second spring" and opportunity for reinvention.
Chapter 14: Menopause Warriors¶
The authors argue that menopause should be reframed from a negative "end" to a positive "second spring." McCall rejects the term "menopause" (meaning "final period") as implying a "full stop" and "black hole," contrasting it with the Japanese concept of "second spring."
Three women are showcased as exemplars of resilience and advocacy. Linzi (age 47) navigated sibling suicide, raising twins, and chronic illness, responding by starting a running club and changing her diet. Adele was misdiagnosed with IBS and depression; her GP dismissed menopause because her periods continued; she self-diagnosed cancer via Google and a private gynaecologist diagnosed perimenopause. Diane Danzebrink experienced surgical menopause with no counselling or follow-up, leading to severe mental health deterioration including suicidal ideation; she founded Menopause Support and launched the #MakeMenopauseMatter campaign.
The chapter describes a protest outside the Houses of Parliament where campaigners pressured the government to reduce the financial burden of HRT prescriptions. The authors claim menopause was included in the English school curriculum in 2019, but provide no data on implementation or impact.
A five-step action plan is provided: be honest, be an ambassador, be an ally, be loud, be proud.
Evidence, examples, and intellectual basis¶
The book's evidence base is overwhelmingly anecdotal. McCall's personal experience and reader-submitted testimonies constitute the primary "evidence" throughout. Medical claims from Dr Potter are presented without citations within the excerpt—no clinical trials, systematic reviews, or peer-reviewed studies are referenced in the supplied text. Statistical claims (e.g., "eight out of ten women experience hot flushes," "1 in 100 women experience POI before age 40") appear without source attribution.
The intellectual basis rests on NICE menopause guidelines (cited as authority for clinical diagnosis and first-line HRT), the British Menopause Society (cited for dismissing alternative tests), and re-analyses of the WHI study (cited for revised risk estimates). The authors' critique of the WHI study is substantively accurate regarding participant age and formulation limitations, but the excerpt does not mention subsequent re-analyses confirming some increased breast cancer risk with combined HRT, especially with longer use.
The book is best classified as popularised advocacy with clinical consultation. It is not a peer-reviewed medical text, nor does it claim to be. The division of labour is explicit: McCall provides personal experience and advocacy; Dr Potter provides "sciencey bits."
Practical recommendations¶
For individuals: Don't wait for periods to stop before seeking help. Recognise that worsening PMS, new anxiety, subtle mood changes, or physical symptoms may be early signs. Push for clinical diagnosis based on symptoms and age rather than blood tests. Explicitly mention "perimenopause" or "menopause" to your doctor. Prepare for appointments with a symptom list and knowledge of NICE guidelines. Consider transdermal HRT (patches, gel, spray) as first-line treatment. If HRT isn't working, revisit your doctor about dosage adjustments. Use topical vaginal oestrogen for vaginal and urinary symptoms. Exercise 30 minutes, 5 days/week. Maintain adequate protein intake (55-60g daily). Consider vitamin D supplementation (1,000iu daily).
For partners: Ask "what can I do to help?" rather than trying to fix things. Understand that symptoms are not "grumpiness" but a medical condition.
For workplaces: Disclose symptoms to colleagues and bosses if comfortable. Ask for workplace support groups and accommodations.
For society: Normalise menopause conversation with partners, children, and young people. Challenge outdated information. Support the #MakeMenopauseMatter campaign.
What is persuasive¶
The book succeeds in validating women's experiences and reducing shame around menopause. The inclusive framing—explicitly including cis women, trans men, non-binary people, women of colour, and those with complex health conditions—is a genuine strength. The critique of medical gaslighting and antidepressant overprescription raises legitimate concerns. The practical guidance on navigating GP appointments (preparing symptom lists, asking about NICE guidelines, seeking second opinions) is actionable and useful. The distinction between systemic and topical HRT, and the explanation of why blood tests are unreliable for perimenopause diagnosis, are medically sound. The cultural perspective from Dr Nighat Arif adds valuable nuance about how menopause is experienced differently across communities.
Limitations, contested claims, and what is missing¶
Overconfidence in HRT: The book presents HRT as a near-universal solution without adequately discussing contraindications (certain cancers, blood clot history), potential side effects, or women for whom HRT is inappropriate or ineffective. The claim that oestrogen-only HRT and body-identical progesterone are "not associated" with increased breast cancer risk is presented as settled fact when the evidence is more nuanced.
Selective use of the WHI study: While correctly noting the study's average participant age was 63, the excerpt does not mention that subsequent re-analyses have confirmed some increased breast cancer risk with combined HRT, especially with longer use. The implication that the study was simply wrong is an oversimplification.
Anecdotal evidence dominates: The book's persuasive force comes from emotional personal stories, not systematic research. No counterexamples are presented—no stories of women for whom HRT failed, who experienced significant side effects, or who successfully managed menopause without medical intervention.
No discussion of non-HRT options: Despite McCall trying herbal remedies, the book does not discuss evidence-based non-hormonal treatments (SSRIs for hot flashes, cognitive behavioural therapy, lifestyle interventions) that might help women who cannot or choose not to take HRT.
Privilege unacknowledged: While McCall notes her privilege in going private, the book does not adequately address structural barriers many women face—cost, access, dismissive GPs, lack of specialist availability—beyond saying she wants to "arm" readers.
Unsupported economic claims: The assertion that a year of HRT costs "around a hundred times less money than a hip replacement" is presented without source, methodology, or consideration of long-term HRT costs, monitoring, or side-effect management.
Contradictions within the text: McCall says menopause "can be fixed so easily" then immediately corrects herself ("actually, I'm lying, it's not that easy at all"). She warns against Googling symptoms while encouraging readers to self-diagnose from her book. She claims she "knew about most symptoms" yet still didn't recognise palpitations as menopausal.
Missing context on dementia claims: The argument that because oestrogen protects against vascular disease, HRT "logically" prevents vascular dementia is speculative. The authors acknowledge "emerging evidence" but do not address contradictory studies or the "timing hypothesis" that HRT may be harmful if started late.
Commercial interests: McCall promotes her own fitness platform (ownyourgoalsdavina.com). Samantha Evans is co-founder of Jo Divine, a sex toy retailer. Specific brand recommendations (Chanel, YSL, LELO) are expensive and presented without acknowledging accessibility limitations.
Bottom line¶
Menopausing is an accessible, emotionally validating introduction to perimenopause and menopause that succeeds in destigmatising the topic and encouraging women to seek help. Its strength lies in community-building and practical advocacy guidance rather than rigorous medical analysis. Readers seeking a balanced, evidence-based treatment of menopause should supplement this book with current clinical guidelines and peer-reviewed research. The book's overconfidence in HRT benefits, underplaying of risks and contraindications, and reliance on anecdotal evidence mean it should be read as a motivational call to action rather than a definitive medical reference. For women feeling isolated and dismissed, it offers valuable validation and a roadmap for self-advocacy. For those seeking nuanced risk-benefit analysis or comprehensive coverage of non-hormonal options, it falls short.